Published in Int J Endocrinol on July 18, 2010
FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res (2012) 1.08
Nutrient transporters: the Achilles' heel of anabolism. Trends Endocrinol Metab (2013) 0.98
Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients. J Transl Med (2013) 0.90
Development of a novel class of glucose transporter inhibitors. J Med Chem (2012) 0.88
Glucosamine-linked near-infrared fluorescent probes for imaging of solid tumor xenografts. Mol Imaging Biol (2012) 0.83
Inositol hexaphosphate inhibits tumor growth, vascularity, and metabolism in TRAMP mice: a multiparametric magnetic resonance study. Cancer Prev Res (Phila) (2012) 0.83
Does expression of glucose transporter protein-1 relate to prognosis and angiogenesis in osteosarcoma? Clin Orthop Relat Res (2014) 0.81
Near-infrared fluorescence and nuclear imaging and targeting of prostate cancer. Transl Androl Urol (2013) 0.81
Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma. J Pathol (2015) 0.80
L-methionase: a therapeutic enzyme to treat malignancies. Biomed Res Int (2014) 0.79
SLC Transporters: Structure, Function, and Drug Discovery. Medchemcomm (2016) 0.79
Loss of Hfe leads to progression of tumor phenotype in primary retinal pigment epithelial cells. Invest Ophthalmol Vis Sci (2013) 0.79
A Potent Glucose-Platinum Conjugate Exploits Glucose Transporters and Preferentially Accumulates in Cancer Cells. Angew Chem Int Ed Engl (2016) 0.79
PK-PD modeling of individual lesion FDG-PET response to predict overall survival in patients with sunitinib-treated gastrointestinal stromal tumor. CPT Pharmacometrics Syst Pharmacol (2016) 0.77
Treating cancer stem cells and cancer metastasis using glucose-coated gold nanoparticles. Int J Nanomedicine (2015) 0.77
The novel IGF-IR/Akt-dependent anticancer activities of glucosamine. BMC Cancer (2014) 0.77
NK cell count and glucotransporter 4 (GLUT4) expression in subjects with type 2 diabetes and colon cancer. Diabetol Metab Syndr (2016) 0.77
K-D:rib dampens Hs 578T cancer cell chemoinvasion and proliferation. Cancer Cell Int (2014) 0.76
Inhibitor Discovery for the Human GLUT1 from Homology Modeling and Virtual Screening. ACS Chem Biol (2016) 0.76
The Robustness of Pathway Analysis in Identifying Potential Drug Targets in Non-Small Cell Lung Carcinoma. Microarrays (Basel) (2014) 0.75
Two-step enzymatic synthesis of 6-deoxy-L-psicose. Tetrahedron Lett (2016) 0.75
Chemical Approach to Positional Isomers of Glucose-Platinum Conjugates Reveals Specific Cancer Targeting through Glucose-Transporter-Mediated Uptake in Vitro and in Vivo. J Am Chem Soc (2016) 0.75
DNA Tumor Viruses and Cell Metabolism. Oxid Med Cell Longev (2016) 0.75
Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors. Cell Metab (2017) 0.75
Loss of Endometrial Sodium Glucose Cotransporter SGLT1 is Detrimental to Embryo Survival and Fetal Growth in Pregnancy. Sci Rep (2017) 0.75
On the origin of cancer cells. Science (1956) 49.55
Cancer's molecular sweet tooth and the Warburg effect. Cancer Res (2006) 7.24
Glycolysis inhibition for anticancer treatment. Oncogene (2006) 6.55
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med (2005) 4.44
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol (2005) 4.37
Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell (2008) 3.95
Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem (2000) 3.74
Insulin-regulatable tissues express a unique insulin-sensitive glucose transport protein. Nature (1988) 3.57
Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science (1987) 3.44
The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet (2007) 3.21
Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet (2006) 2.94
Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J Biol Chem (1995) 2.89
2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res (2004) 2.88
Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther (2008) 2.79
mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes (2008) 2.64
Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr (2003) 2.62
The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch (2003) 2.58
The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res (2004) 2.56
Insulin-regulated glucose uptake in rat adipocytes is mediated by two transporter isoforms present in at least two vesicle populations. J Biol Chem (1989) 2.39
Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer (2003) 2.37
Exercise induces recruitment of the "insulin-responsive glucose transporter". Evidence for distinct intracellular insulin- and exercise-recruitable transporter pools in skeletal muscle. J Biol Chem (1990) 2.27
Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer (1993) 2.26
Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet (2008) 2.21
Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem (2004) 2.18
Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer (1997) 1.97
Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer (2001) 1.96
Regulation of the fructose transporter GLUT5 in health and disease. Am J Physiol Endocrinol Metab (2008) 1.92
Decreased expression of the insulin-responsive glucose transporter in diabetes and fasting. Nature (1989) 1.88
Differential gene expression profiling in human brain tumors. Physiol Genomics (2001) 1.88
The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. JPEN J Parenter Enteral Nutr (2004) 1.86
The facilitative glucose transporter GLUT3: 20 years of distinction. Am J Physiol Endocrinol Metab (2008) 1.82
Identification of an intracellular pool of glucose transporters from basal and insulin-stimulated rat skeletal muscle. J Biol Chem (1990) 1.77
Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res (2003) 1.69
GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer (1998) 1.68
Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol (2006) 1.51
GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res (1996) 1.42
Identification of a mammalian H(+)-myo-inositol symporter expressed predominantly in the brain. EMBO J (2001) 1.41
Insulin-stimulated translocation of glucose transporter (GLUT) 12 parallels that of GLUT4 in normal muscle. J Clin Endocrinol Metab (2009) 1.36
The tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptake. Am J Pathol (2008) 1.33
Identification of a novel glucose transporter-like protein-GLUT-12. Am J Physiol Endocrinol Metab (2002) 1.32
GLUT8 contains a [DE]XXXL[LI] sorting motif and localizes to a late endosomal/lysosomal compartment. Traffic (2005) 1.24
Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc Natl Acad Sci U S A (2009) 1.23
A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol Cancer Ther (2008) 1.21
Differential expression of the GLUT1 and GLUT4 glucose transporters during differentiation of L6 muscle cells. Biochem Biophys Res Commun (1991) 1.21
Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. Brain Res Mol Brain Res (1994) 1.20
Hexose transporter mRNAs for GLUT4, GLUT5, and GLUT12 predominate in human muscle. Am J Physiol Endocrinol Metab (2006) 1.20
Intracellular localization and properties of particulate hexokinase in the Novikoff ascites tumor. Evidence for an outer mitochondrial membrane location. J Biol Chem (1983) 1.20
Expression of the fructose transporter GLUT5 in human breast cancer. Proc Natl Acad Sci U S A (1996) 1.16
Expression of glucose transporters in head-and-neck tumors. Int J Cancer (1994) 1.12
Dual control of glut1 glucose transporter gene expression by hypoxia and by inhibition of oxidative phosphorylation. J Biol Chem (1997) 1.11
Sugar and amino acid transport by cells in culture--differences between normal and malignant cells. N Engl J Med (1972) 1.11
Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer (2003) 1.10
Sequence and functional analysis of GLUT10: a glucose transporter in the Type 2 diabetes-linked region of chromosome 20q12-13.1. Mol Genet Metab (2001) 1.09
Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer (2003) 1.08
GLUT14, a duplicon of GLUT3, is specifically expressed in testis as alternative splice forms. Genomics (2002) 1.07
GLUT8, the enigmatic intracellular hexose transporter. Am J Physiol Endocrinol Metab (2009) 1.06
Facilitative glucose transporter 9 expression affects glucose sensing in pancreatic beta-cells. Endocrinology (2009) 1.05
Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas (2008) 1.05
Distribution of the glucose transporters in human brain tumors. Cancer Res (1992) 1.03
Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid (2004) 1.02
Facilitative glucose transporter 9, a unique hexose and urate transporter. Am J Physiol Endocrinol Metab (2009) 1.02
GLUT7: a new intestinal facilitated hexose transporter. Am J Physiol Endocrinol Metab (2008) 1.01
Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery (2004) 1.01
Differential expression of facilitative glucose transporters in normal and tumour kidney tissues. BJU Int (2007) 0.99
Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer (1999) 0.97
Characterization of the human SLC2A11 (GLUT11) gene: alternative promoter usage, function, expression, and subcellular distribution of three isoforms, and lack of mouse orthologue. Mol Membr Biol (2005) 0.96
Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1 alpha. BJU Int (2007) 0.96
Human articular chondrocytes express three facilitative glucose transporter isoforms: GLUT1, GLUT3 and GLUT9. Cell Biol Int (2002) 0.95
Erythroid glucose transporters. Curr Opin Hematol (2009) 0.95
Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology (2001) 0.95
GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol (2006) 0.94
Recruitment of GLUT-4 glucose transporters by insulin in diabetic rat skeletal muscle. Biochem Biophys Res Commun (1990) 0.94
Differential expression of GLUT12 in breast cancer and normal breast tissue. Cancer Lett (2003) 0.92
Inhibition of cell proliferation in human breast tumor cells by antisense oligonucleotides against facilitative glucose transporter 5. J Cell Biochem (2004) 0.92
SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn J Cancer Res (2001) 0.92
Expression of glucose transporter-1 and -3 in the head and neck carcinoma--the correlation of the expression with the biological behaviors. ORL J Otorhinolaryngol Relat Spec (2008) 0.91
Differential expression of facilitative glucose transporter (GLUT) genes in primary lung cancers and their liver metastases. Jpn J Cancer Res (1999) 0.91
Essential role of glucose transporter GLUT3 for post-implantation embryonic development. J Endocrinol (2008) 0.90
Disease activity and 18F-FDG uptake in organising pneumonia: semi-quantitative evaluation using computed tomography and positron emission tomography. Eur J Nucl Med Mol Imaging (2006) 0.89
Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. Cancer Invest (2008) 0.89
Genetic analysis of the GLUT10 glucose transporter (SLC2A10) polymorphisms in Caucasian American type 2 diabetes. BMC Med Genet (2005) 0.88
Expression of glucose transporter 5 by microglia in human gliomas. Neuropathol Appl Neurobiol (2004) 0.86
Prognostic implications of glucose transporter protein-1 (glut-1) overexpression in bone and soft-tissue sarcomas. Jpn J Clin Oncol (2007) 0.86
Developmental expression of insulin-regulatable glucose transporter GLUT-4. Am J Physiol (1992) 0.86
Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract. Pathol Res Pract (2009) 0.85
Evaluation of SLC2A10 (GLUT10) as a candidate gene for type 2 diabetes and related traits in Finns. Mol Genet Metab (2005) 0.85
Association study of genetic polymorphisms of SLC2A10 gene and type 2 diabetes in the Taiwanese population. Diabetologia (2006) 0.85
Expression of GLUT12 in the fetal membranes of the human placenta. Placenta (2005) 0.84
Expression of GLUT1 in primary renal tumors: morphologic and biologic implications. Am J Clin Pathol (2007) 0.84
Genetic variation of the GLUT10 glucose transporter (SLC2A10) and relationships to type 2 diabetes and intermediary traits. Diabetes (2003) 0.83
Deoxyglucose kinetics in a rat brain tumor. J Cereb Blood Flow Metab (1989) 0.83
Evaluation of expression and function of the H+/myo-inositol transporter HMIT. BMC Cell Biol (2009) 0.82
Studies of relationships between the GLUT10 Ala206Thr polymorphism and impaired insulin secretion. Diabet Med (2005) 0.81
Growth inhibition of head and neck carcinomas by D-allose. Head Neck (2009) 0.81
Alterations in glucose transporter expression and function in diabetes: mechanisms for insulin resistance. J Cell Biochem (1992) 0.80
Tumor localization with 18F-2-fluoro-2-deoxy-D-glucose: comparative autoradiography, glucose 6-phosphatase histochemistry, and histology of renally implanted sarcoma of the rat. Res Exp Med (Berl) (1985) 0.79
Expression of Na(+)-coupled sugar transport in HT-29 cells: modulation by glucose. Am J Physiol (1991) 0.78
An intracellular motif of GLUT4 regulates fusion of GLUT4-containing vesicles. BMC Cell Biol (2008) 0.77
Glucose transporter proteins in human insulinoma. Ann Intern Med (1994) 0.77
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs (2010) 1.34
Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med (2012) 1.31
Casein kinase 1 is a novel negative regulator of E-cadherin-based cell-cell contacts. Mol Cell Biol (2007) 1.30
The transcriptional repressor Glis2 is a novel binding partner for p120 catenin. Mol Biol Cell (2007) 1.18
New insights into molecular mechanisms of sunitinib-associated side effects. Mol Cancer Ther (2011) 1.16
A novel procedure for protein extraction from formalin-fixed paraffin-embedded tissues. Proteomics (2011) 1.01
Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer. Int J Oncol (2011) 0.91
Circulating microRNAs: molecular microsensors in gastrointestinal cancer. Sensors (Basel) (2012) 0.89
Circulating levels of GDF15, MMP7 and miR-200c as a poor prognostic signature in gastric cancer. Future Oncol (2014) 0.89
miR-203 regulates cell proliferation through its influence on Hakai expression. PLoS One (2012) 0.88
Comprehensive lung injury pathology induced by mTOR inhibitors. Clin Transl Oncol (2009) 0.87
Evaluation of the adenocarcinoma-associated gene AGR2 and the intestinal stem cell marker LGR5 as biomarkers in colorectal cancer. Int J Mol Sci (2012) 0.86
Inhibition of proliferation and expression of T1 and cyclin D1 genes by thyroid hormone in mammary epithelial cells. Mol Carcinog (2002) 0.86
Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity. Anticancer Drugs (2012) 0.85
Colorectal cancer: response to sunitinib in a heavily pretreated colorectal cancer patient. Anticancer Drugs (2010) 0.84
Immune microenvironment in colorectal cancer: a new hallmark to change old paradigms. Clin Dev Immunol (2011) 0.83
Posttranscriptional regulation by RNA-binding proteins during epithelial-to-mesenchymal transition. Cell Mol Life Sci (2013) 0.83
Biological influence of Hakai in cancer: a 10-year review. Cancer Metastasis Rev (2012) 0.83
Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor. Expert Opin Biol Ther (2013) 0.81
Evaluation of plakophilin-3 mRNA as a biomarker for detection of circulating tumor cells in gastrointestinal cancer patients. Cancer Epidemiol Biomarkers Prev (2010) 0.81
Glucose transporter expression and the potential role of fructose in renal cell carcinoma: A correlation with pathological parameters. Mol Med Rep (2011) 0.81
Hakai reduces cell-substratum adhesion and increases epithelial cell invasion. BMC Cancer (2011) 0.80
Sunitinib-induced asthenia: from molecular basis to clinical relief. Cancer Biol Ther (2011) 0.75